0Q15 Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 0Q15 from our risk checks.
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$106.47 |
| 52 Week High | US$121.60 |
| 52 Week Low | US$89.74 |
| Beta | 0.74 |
| 1 Month Change | -6.44% |
| 3 Month Change | -6.92% |
| 1 Year Change | -5.69% |
| 3 Year Change | -9.55% |
| 5 Year Change | n/a |
| Change since IPO | 1,062.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Q15 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -0.4% | -5.5% | 1.1% |
| 1Y | -5.7% | -13.5% | 1.9% |
Return vs Industry: 0Q15 exceeded the UK Medical Equipment industry which returned -13.9% over the past year.
Return vs Market: 0Q15 underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
| 0Q15 volatility | |
|---|---|
| 0Q15 Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0Q15 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0Q15's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| 0Q15 fundamental statistics | |
|---|---|
| Market cap | US$183.88b |
| Earnings (TTM) | US$5.61b |
| Revenue (TTM) | US$40.33b |
32.9x
P/E Ratio4.6x
P/S RatioIs 0Q15 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Q15 income statement (TTM) | |
|---|---|
| Revenue | US$40.33b |
| Cost of Revenue | US$18.03b |
| Gross Profit | US$22.29b |
| Other Expenses | US$16.68b |
| Earnings | US$5.61b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.23 |
| Gross Margin | 55.28% |
| Net Profit Margin | 13.91% |
| Debt/Equity Ratio | 40.9% |
How did 0Q15 perform over the long term?
See historical performance and comparison